AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$RVTY

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

Original reporting
investing.com
Published Nov 3, 2026, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for revenue growth and margin expansion, likely prompting buying interest.

02

Market read

First‑report earnings with guidance lift for a mid‑cap US stock; material impact on the healthcare equipment sector.

03

What to watch

Potential headwinds from the China Immunodiagnostics divestiture and FX could temper long‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Revvity (RVTY) is a life‑sciences and diagnostics company that recently announced AI‑related product enhancements and an acquisition.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity reported Q3 2026 results beating expectations and raised full-year guidance, causing an 8.85% pre‑market stock surge.

Expected impact

upward pressure as the market prices in higher revenue and margin outlook

Evidence & confidence

Revenue beat, margin expansion, and guidance lift are fresh, material data for a mid‑cap stock.

Market effects

Sector

Life‑sciences and diagnostics peers may see renewed interest as Revvity signals stronger AI‑driven demand.

Regional

Positive momentum in Europe and the Americas could lift related biotech and instrument makers.

Global

Guidance lift adds optimism to the broader healthcare equipment sector worldwide.

Counterpoint

What could challenge this read

If the market has already priced in the beat, the stock could face short‑term profit‑taking.

Key entities

  • company
    Revvity Inc.

    Life‑sciences and diagnostics firm reporting Q3 2026 results.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min
NOV 3
$RVTYHighAI 8/10

Why is Revvity stock surging today?

Revvity (RVTY) stock rose 8.8% in pre-market trading after its Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 and revenue of $729M. The company raised its full-year guidance, citing strong segment growth and margin expansion. CEO Prahlad Singh highlighted broad-based growth. The move was driven by company-specific news, not broader market trends. TD Cowen had previously raised its price target to $175.

investing.com2 min